COVID-19 Impacts on Pricing and Access

15:00
COVID-19 Response Dialogue: Accelerating Speed to Market, Drug Accessibility and Affordability

• Assessing regulator’s priority, managing delays and disruption on appraisals
• Not so new normal: Impediments to commercialising drugs at the same speed and scale
• Donation and pricing commitments from pharma manufacturers
• Developments in Government pricing and reimbursement
• How will pharma price the affordable therapeutics against COVID-19?

Moderator:
Alexander Zach, Senior Vice President, Global Head of Market Access and Policy, Biocon, India

Panellists:
Yelitte Ho, Australian Pharmacist and Pharmaceutical Policy Advisor, Australia
Sayantani Dasgupta, Associate Director, Customer Engagement Strategy & Commercial Excellence, Merck, Japan
Viviendouf Koh, Regional Marketing Manager, South and East Asia, Lundbeck, Singapore
Jek Fong, Director, Market Access and Personalised Healthcare, Roche, Singapore
More panellists to be confirmed

15:40
Managing the Effects of COVID-19 on Drug Access

• Propagating international access for drugs
• Improving access for high cost drugs – will it be the case for coronavirus treatments? -Creating innovative value
• Overcoming access difficulties in regions

Alexander Zach, Senior Vice President, Global Head of Market Access and Policy, Biocon, India

16:10
Case study of Greater Access – Merck and The Jenner Institute COVID-19 Vaccine Manufacturing

• Redefine, transform and innovate pharma business strategy for greater access
• Adjusting commercial models- patient-physician relationships
• Catering to high population markets

Sayantani Dasgupta, Associate Director, Customer Engagement Strategy & Commercial Excellence, Merck, Japan

16:40
Gilead Science Case Study:
COVID-19: Ramping up Remdesivir Production for Affordable Access and Pricing

17:10
Roche’s Case Study: Approaches for Urgency to Market in the Fight Against COVID-19

• Beyond the antibody test
• Case study- drug development and access acceleration

Jek Fong, Director, Market Access and Personalised Healthcare, Roche, Singapore

End of Virtual Conference Day 1

Agile Market Access

13:00
Agile and Increased Capability for Market Access for Non-COVID Drugs

• Working in the era of changed business models, price negotiation and FDA’s shifting priorities
• Strengthening regional health systems with partnerships
• Regional case studies- challenges and opportunities
• Strategies to introduce biosimilars into Asia

Mark Tennyson, JAPAC Regional Head, Value, Access and Policy, Amgen, Hong Kong

13:30
Dealing with COVID-19 and Drug Access in Indonesia

• Managing access and supply disruption for usual drugs
• Pricing and gaining access for COVID-19 related drugs
• Product commercialisation risks during and post-COVID

Rizman Abudaeri, Director, Market Access, Government and Regulatory Affair, AstraZeneca, Indonesia

14:00
Fair Pricing and Drug Affordability Whilst Satisfying Governments Healthcare Policy  

• ASEAN and Asia market analysis
• Working with different reimbursement regimes – Aiming for a Win-Win situation
• Managing drug development costs, investments and ROIs
• Improving drug access and copayment- What is the right balance?
• Developed vs emerging market landscapes: What are the key considerations for growth

Moderator:
Jun Feng, Market Access Associate Director, Oncology, JAPAC, AbbVie, Singapore  

Panellists:
Mark Tennyson, JAPAC Regional Head, Value, Access and Policy, Amgen, Hong Kong
Nathan K, Market Access and Government Affairs Director, Johnson & Johnson, Malaysia
Judy Deng, Head of Market Access, Oncology, Novartis, China
Rizman Abudaeri, Director, Market Access, Government and Regulatory Affair, AstraZeneca, Indonesia

14:40
China’s Drug Landscape – The Medical Insurance Reform of Tripartite System and Implications for Market Access

• Access for innovative therapies in China
• What are CFDA’s priorities?
• Practical considerations and negotiations for placement onto the list of National Reimbursement Drug List (NRDL)
• Proving value for innovative therapies
• China case study: Managing access for cancer drugs post COVID-19 outbreak

Judy Deng, Head of Market Access, Oncology, Novartis, China

15:00
Online Networking and Stretch Break

15:30
Early access of rare disease treatment: balance between financial sustainability and social responsibility

Carol Chu, Head of VD&A, Communication and Patient Advocacy, Shire

16:00
Oncology Market Access and Pricing Strategies – Addressing Risks in  Commercialisation

Jun Feng, Market Access Associate Director, Oncology, JAPAC, AbbVie, Singapore

16:30
Global Strategy on Pharma Marketing and Agile Product Launch Strategy

For speaking enquiry, please contact Yvonne.Leong@informa.com

17:10
Oncology and COVID-19: Setting the Priority Right

• Building access to cancer care in emerging markets
• India’s case study: Rat race between oncology drugs and COVID-19
• Building portfolio and connecting with customers
• Using digital tools and access strategies

Anupama Rao Singh, Director, Oncology and Hospital CoE, Global Generics, Emerging Markets, Dr Reddys, India

17:40
End of Day 2 Virtual Conference                                                                                                                                                                              

Payer and Reimbursement

13:00
Case Study:
Lundbeck’s Value Creation Strategies in Asia 

• Working with payers, patients and reimbursement bodies for creating customer-focused values
• Value creation for disease area of psychiatry
• Lowering stigma for treatments in neurology and psychiatry

 Viviendouf Koh, Regional Marketing Manager, South and East Asia, Lundbeck, Singapore

13:30
Pharma Partnerships for Affordable Healthcare 

For speaking enquiry, please contact Yvonne.Leong@informa.com

14:00
Australia Case Study:
COVID-19 Government, Reimbursement & Regulatory Updates 

• COVID-19 in Australia
• Universal access to healthcare in Australia and the Pharmaceutical Benefits Scheme (PBS)
• Universal Subsidy Scheme for Medicines
• How does a drug get listed on the PBS (registration process, pricing, listing consideration)?
• Key factors influencing decision making by the independent Pharmaceutical Benefits Advisory Committee
• Patent and data protection of pharmaceuticals in Australia

Yelitte Ho, Australian Pharmacist and Pharmaceutical Policy Advisor, Australia   

Optimising RWE and HTA         

 14:30
Demonstrating Value and Data Gathering for RWE in Asia

• Understand how RWE is different from randomized control trials (RCTs)
• How do Regulatory bodies consider the use of RWE for decision making?
• Challenges to collect RWE; how to access and when to use do we have that ready in Asia
• Successful regional case studies

Kim Soyoung, Director HEOR, Medical Affairs, Asia & Oceania, Astellas Pharma, Singapore

15:00
Online Networking and Stretch Break

15:30
Use of Real-World Evidence in the Drug Registration Process 

• What’s real World Data, Real world Evidence?
• How is Real World Evidence generated?
• Overview of Regulations (US FDA, EMA, China NMPA)

Gaelle Richer, Director Global Regulatory Affairs, GSK, Singapore

16:00
HTA for Growing Economies

• Challenges and Opportunities of using HTA
• Key areas of focus for emerging markets
• Maximising the returns of HTA on proving drug value

Nathan K, Market Access and Government Affairs Director, Johnson & Johnson, Malaysia

Diversity and Inclusion in Pharma

16:40
Cultivating the Next-Gen of Women Leaders in Pharma

• Why does gender equality matter on the board?
• Key challenges facing women leaders in Pharma
• Management efforts to address some of these challenges, and remaining gaps
• Reflections on the journey to the top
• Breaking the glass ceiling: Lessons learnt along the way, and advice to my younger self
• Management efforts to address some of these challenges, and remaining gaps

Panelists:
Anupama Rao Singh, Director, Oncology and Hospital CoE, Global Generics, Emerging Markets, Dr. Reddy’s Laboratories, India
Angela Brady, Director of Innovation Research, APAC R&D, GSK, Singapore
Chandana Yeluri, Head- Digital and Continuous Improvement, Sandoz Development Center, Novartis, India
More panelists to be confirmed

17:40
End of Day 3 Virtual Conference